Hikma Pharmaceuticals Plc Hikma announces agreement with Chiesi Group
January 13 2020 - 3:00AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
13 January 2020
London, 13 January 2020 - Hikma Pharmaceuticals PLC (Hikma,
Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated
Ba1/stable Moody's and BB+/positive S&P) the multinational
pharmaceutical company, today announced an exclusive licensing and
distribution agreement with Chiesi Farmaceutici, a research-focused
international pharmaceutical Group (Chiesi Group), headquartered in
Italy.
The agreement provides Hikma with exclusive rights to
commercialise 11 of Chiesi's leading products in Egypt, including
currently marketed and pipeline products. This builds on Hikma's
existing partnership with Chiesi in Morocco and adds a range of
innovative products to its Egyptian portfolio, including Foster(R)
, Foster Nexthaler(R) , Trimbow(R) and Curosurf(R) .
Mazen Darwazah, Hikma's Executive Vice Chairman and President of
MENA said, "We are very pleased to be partnering with Chiesi to
commercialise a range of specialty products, primarily in
respiratory and neonatal therapeutic areas, in Egypt. This supports
our strategy of working with global partners to strengthen our
portfolio in growing therapeutic categories. In particular, this
agreement enables us to meet the needs of a growing number of
patients suffering from asthma and COPD in Egypt and improve their
access to high-quality medicines."
Ugo Di Francesco, CEO of Chiesi Group commented: "We are really
proud to have strengthened our strategic partnership with Hikma.
This will allow us to increase the availability of our main
therapeutic solutions in the respiratory and neonatology fields to
Egyptian patients. The agreement highlights our continued progress
against Chiesi Group's main mission: addressing population health
needs around the world."
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal +44 (0)20 7399 2760/ +44 7776
EVP, Strategic Planning and 477050
Global Affairs uk-investors@hikma.com
Dana Alhusseini +962 6 580 2900
Communication Manager Dalhusseini@hikma.com
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we're a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,400 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit www.hikma.com.
About Chiesi Group
Based in Parma, Italy, Chiesi Farmaceutici is an international
research-oriented group with over 80 years of experience in the
pharmaceutical sector, operating in 28 countries. The Group
conducts research, develops and markets innovative drugs for
respiratory treatment, Special Care medicine and rare diseases. The
Group's Research and Development Centre is based in Parma and
integrates its work with that of 6 other important R&D groups
in France, the USA, the UK and Sweden to promote its own
pre-clinical, clinical and registration programmes. The Chiesi
Group is a certified B Corp and employs around 5,700 people. For
further information please visit www.chiesi.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASFEFWEESSEEF
(END) Dow Jones Newswires
January 13, 2020 03:00 ET (08:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Sep 2023 to Sep 2024